Japanese generics market consolidates

Japan-based pharmaceutical groups Nichi-Iko Pharmaceutical and Eisai have announced a strategic partnership in the generics business. As part of the agreement, Eisai will sell its subsidiary Elmed Eisai–manufacturing generics–to Nichi Iko for €130m (JY17.12bn). As part of the agreement, the companies will create a new business model to co-market generics. The agreement strengthens Nichi’s role in the generics business and allows Eisai to focus on prescription drugs.

(Source: Eisai)